Accolade Is Maintained at Buy by Guggenheim
Accolade Is Maintained at Buy by Guggenheim
Accolade Price Target Cut to $13.00/Share From $17.00 by Guggenheim
Accolade Price Target Cut to $13.00/Share From $17.00 by Guggenheim
Guggenheim: Maintaining the Accolade (ACCD.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $17.00 to $13.00.
Guggenheim: Maintaining the Accolade (ACCD.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $17.00 to $13.00.
Guggenheim Maintains Buy on Accolade, Lowers Price Target to $13
Guggenheim analyst Sandy Draper maintains Accolade (NASDAQ:ACCD) with a Buy and lowers the price target from $17 to $13.
Accolade Is Maintained at Equal-Weight by Wells Fargo
Accolade Is Maintained at Equal-Weight by Wells Fargo
Wells Fargo: Maintaining the Accolade (ACCD.US) rating, adjusted from a wait-and-see shareholding rating to a shareholding wait-and-see rating, and the target price was adjusted from $12.00 to $10.00.
Wells Fargo: Maintaining the Accolade (ACCD.US) rating, adjusted from a wait-and-see shareholding rating to a shareholding wait-and-see rating, and the target price was adjusted from $12.00 to $10.00.
Wells Fargo Maintains Equal-Weight on Accolade, Lowers Price Target to $10
Wells Fargo analyst Stan Berenshteyn maintains Accolade (NASDAQ:ACCD) with a Equal-Weight and lowers the price target from $12 to $10.
Accolade, Inc.'s (NASDAQ:ACCD) Latest 14% Decline Adds to One-year Losses, Institutional Investors May Consider Drastic Measures
Key Insights Significantly high institutional ownership implies Accolade's stock price is sensitive to their trading actions 54% of the business is held by the top 8 shareholders Analyst forecast
EDIT, CLNE and NIU Are Among After Hour Movers
Why Aon Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Aon plc (NYSE:AON) fell sharply during Friday's session after the company reported worse-than-expected quarterly financial results.Aon posted adjusted earnings of $5.66 per share, missing ma
Earnings Call Summary | Accolade(ACCD.US) Q4 2024 Earnings Conference
The following is a summary of the Accolade, Inc. (ACCD) Q4 2024 Earnings Call Transcript:Financial Performance:Accolade Inc. reported Q4 revenue of $125 million, a 30% pro forma growth over the same p
Morgan Stanley Trims Accolade's Price Target to $12 From $13, Maintains Equal Weight Rating
Accolade (ACCD) has an average rating of outperform and price targets ranging from $10 to $18, according to analysts polled by Capital IQ. Price: 7.92, Change: -1.27, Percent Change: -13.82
12 Health Care Stocks Moving In Friday's Intraday Session
GainersBiodexa Pharmaceuticals (NASDAQ:BDRX) stock rose 61.4% to $1.17 during Friday's regular session. The company's market cap stands at $5.1 million. Agenus (NASDAQ:AGEN) shares rose 32.53% to $11.
Accolade Price Target Cut to $11.00/Share From $13.00 by Barclays
Accolade Price Target Cut to $11.00/Share From $13.00 by Barclays
Barclays: Maintaining the Accolade (ACCD.US) rating, adjusted from a wait-and-see shareholding rating to a shareholding wait-and-see rating, and the target price was adjusted from $13.00 to $11.00.
Barclays: Maintaining the Accolade (ACCD.US) rating, adjusted from a wait-and-see shareholding rating to a shareholding wait-and-see rating, and the target price was adjusted from $13.00 to $11.00.
Accolade Is Maintained at Buy by Needham
Accolade Is Maintained at Buy by Needham
Needham Maintains Buy on Accolade, Lowers Price Target to $13
Needham analyst Ryan MacDonald maintains Accolade with a Buy and lowers the price target from $17 to $13.
Barclays Remains a Hold on Accolade (ACCD)
Accolade Inc (ACCD) Q4 2024 Earnings Call Transcript Highlights: Record Revenue and Strategic ...
Accolade Inc (ACCD) Surpasses Revenue Expectations and Narrows Losses in Fiscal Q4 and Full ...
No Data